Compare Tango Therapeutics Inc. (TNGX) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Uranium Energy Corp — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Uranium Energy Corp trades at $7.7 (market cap $4.08B). The key difference: Tango Therapeutics Inc. and Uranium Energy Corp are close in size by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Uranium Energy Corp for 38 Days on average.
| TNGX | UEC | |
|---|---|---|
Market Cap | $3.75B | $4.08B |
Volume | 9,619,106 | 14,920,249 |
Sector | Health | Energy |
52-Week High | $32.90 | $20.14 |
52-Week Low | $7.50 | $7.70 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $2.77B | $3.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Uranium Energy (UEC) trades at $8.25, down 6.57% today, amid bearish technical signals despite strong analyst support. The company shows operational improvements with multi-mine expansion but faces fundamental challenges with negative net income margins (-368.62%) and declining revenue from $67M in 2025 to $37M in 2026. Recent Q4 2026 earnings beat revenue estimates but missed on EPS, while technical indicators show 18 sell signals versus 3 buy signals.
The stock presents a high-risk opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting with weak financials. Key risks include unsustainable production growth, dependence on inventory sales, and cash flow challenges. Upside depends on successful execution of uranium production ramp-up and favorable government demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
